Paper33330100
Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease.
Suresh D and 2 others. Front Oncol, 2020. Cited by 141 papers, by iCite.
Cite this record
ConductScience Library. Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease. Papers, record 33330100. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33330100
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References110
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32486341 | Lipid Metabolism in Development and Progression of Hepatocellular Carcinoma. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32486341 | PubMed |
| 2 | 15565570 | Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. | Hepatology | 2004 | https://conductscience.org/library/papers/15565570 | PubMed |
| 3 | 30658729 | Hepatocellular carcinoma in the setting of alcohol-related liver disease. | J Hepatol | 2019 | https://conductscience.org/library/papers/30658729 | PubMed |
| 4 | 30119271 | Diabetes and hepatocellular carcinoma: A pathophysiological link and pharmacological management. | Biomed Pharmacother | 2018 | https://conductscience.org/library/papers/30119271 | PubMed |
| 5 | 8921985 | Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. | Mutat Res | 1996 | https://conductscience.org/library/papers/8921985 | PubMed |
| 6 | 28983565 | The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. | JAMA Oncol | 2017 | https://conductscience.org/library/papers/28983565 | PubMed |
| 7 | 27986466 | Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies. | Trends Endocrinol Metab | 2017 | https://conductscience.org/library/papers/27986466 | PubMed |
| 8 | 29359013 | Molecular basis of hepatocellular carcinoma induced by hepatitis C virus infection. | World J Hepatol | 2017 | https://conductscience.org/library/papers/29359013 | PubMed |
| 9 | 22467277 | Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease. | Hepatology | 2012 | https://conductscience.org/library/papers/22467277 | PubMed |
| 10 | 24978903 | TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. | Nat Commun | 2014 | https://conductscience.org/library/papers/24978903 | PubMed |
| 11 | 16447287 | Nonalcoholic fatty liver disease: from steatosis to cirrhosis. | Hepatology | 2006 | https://conductscience.org/library/papers/16447287 | PubMed |
| 12 | 31728429 | Hepatocellular carcinoma in alcoholic and non-alcoholic fatty liver disease-one of a kind or two different enemies? | Transl Gastroenterol Hepatol | 2019 | https://conductscience.org/library/papers/31728429 | PubMed |
| 13 | 31060311 | Role of Gut Microbiota in Hepatocarcinogenesis. | Microorganisms | 2019 | https://conductscience.org/library/papers/31060311 | PubMed |
| 14 | 16527702 | The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. | Clin Gastroenterol Hepatol | 2006 | https://conductscience.org/library/papers/16527702 | PubMed |
| 15 | 31024205 | Hepatocellular Carcinoma: Etiology and Current and Future Drugs. | J Clin Exp Hepatol | 2019 | https://conductscience.org/library/papers/31024205 | PubMed |
| 16 | 12390068 | Racial and ethnic differences in alcohol-associated aspartate aminotransferase and gamma-glutamyltransferase elevation. | Arch Intern Med | 2002 | https://conductscience.org/library/papers/12390068 | PubMed |
| 17 | 12395331 | Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. | Hepatology | 2002 | https://conductscience.org/library/papers/12395331 | PubMed |
| 18 | 23162602 | Alpha-1-antitrypsin in pathogenesis of hepatocellular carcinoma. | Hepat Mon | 2012 | https://conductscience.org/library/papers/23162602 | PubMed |
| 19 | 30076710 | MicroRNAs in alcoholic liver disease: Recent advances and future applications. | J Cell Physiol | 2018 | https://conductscience.org/library/papers/30076710 | PubMed |
| 20 | 9482507 | 4-Aminobiphenyl DNA damage in liver tissue of hepatocellular carcinoma patients and controls. | Am J Epidemiol | 1998 | https://conductscience.org/library/papers/9482507 | PubMed |
Cited by113
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 141 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42827771 | Scoparone protects against acetaminophen-induced acute liver injury: Insights from In vivo experiments and RNA sequencing. | Biochem Biophys Rep | 2026 | https://conductscience.org/library/papers/42827771 | PubMed |
| 42591901 | Palmitoylation-related gene signature for immune subtyping, prognostic stratification, and immunotherapy guidance in hepatocellular carcinoma. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42591901 | PubMed |
| 42449680 | The Effect of Statin Therapy on the Overall Survival of Patients with Hepatocellular Carcinoma: A Single-Center Experience. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42449680 | PubMed |
| 42395637 | Emerging role of proteomics in advancing diagnosis, prognosis, and treatment of liver cancer. | Liver Res | 2026 | https://conductscience.org/library/papers/42395637 | PubMed |
| 42371299 | Decoding the functional landscape of long non-coding RNAs in hepatocellular carcinoma: molecular mechanisms, clinical implications, and therapeutic prospects. | J Egypt Natl Canc Inst | 2026 | https://conductscience.org/library/papers/42371299 | PubMed |
| 42166032 | Advanced liposomal nanoplatforms for flavonoid delivery: a mechanistic and comparative perspective in hepatocellular carcinoma. | Discov Oncol | 2026 | https://conductscience.org/library/papers/42166032 | PubMed |
| 42046763 | Trans-Arterial Chemoembolization Combined with Microwave Ablation versus Microwave Ablation Alone for 3-5 cm Hepatocellular Carcinoma: A Multicenter Retrospective Study. | J Hepatocell Carcinoma | 2026 | https://conductscience.org/library/papers/42046763 | PubMed |
| 41937404 | Meta-Analysis of Genetic Variants Associated With HBV Infection Susceptibility and Hepatocellular Carcinoma Risk. | J Viral Hepat | 2026 | https://conductscience.org/library/papers/41937404 | PubMed |
| 41822854 | Therapeutic Potential of Silver Nanoparticles in Hepatocellular Carcinoma: From Pathogenesis to Clinical Perspectives. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/41822854 | PubMed |
| 41810934 | Mechanisms of Action and Biomarker Potential of ncRNAs in Hepatocellular Carcinoma and Liver Fibrosis: A Review. | Anal Cell Pathol (Amst) | 2026 | https://conductscience.org/library/papers/41810934 | PubMed |
| 41808116 | ICMT deficiency ameliorates weight loss and mortality, but not tumor formation in a mouse model of liver cancer. | Cell Commun Signal | 2026 | https://conductscience.org/library/papers/41808116 | PubMed |
| 41647281 | Immune checkpoint inhibition (ICI) in current systemic therapies for hepatocellular carcinoma (HCC). | ESMO Gastrointest Oncol | 2023 | https://conductscience.org/library/papers/41647281 | PubMed |
| 41639358 | Temporal trends and regional variations in hepatocellular carcinoma etiology: a multinational study across Asia. | Hepatol Int | 2026 | https://conductscience.org/library/papers/41639358 | PubMed |
| 41602129 | Metabolites involvement in the growth and spread of liver cancer. | Liver Res | 2025 | https://conductscience.org/library/papers/41602129 | PubMed |
| 41589205 | Role of insulin-like growth factor/receptor signaling in hepatocellular carcinoma. | Hepatol Forum | 2026 | https://conductscience.org/library/papers/41589205 | PubMed |
| 41527027 | Hepatic loss of AATF attenuates MASH by suppressing AKT-mTORC1 signaling and reprogramming lipid metabolism. | Mol Med | 2026 | https://conductscience.org/library/papers/41527027 | PubMed |
| 41526557 | Pathobiological Dictionary Defining Pathomics and Texture Features: Addressing Understandable AI Issues in Personalized Liver Cancer; Dictionary Version LCP1.0. | J Imaging Inform Med | 2026 | https://conductscience.org/library/papers/41526557 | PubMed |
| 41465202 | Putative Role of Fatty Acid Metabolic Therapy Using Ketogenic Diet and HIF-1α Inhibition in Hepatocellular Carcinoma: Evidence from an In Vitro Study. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41465202 | PubMed |
| 41462859 | Atezolizumab Plus Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma: An Institutional Experience. | Biomedicines | 2025 | https://conductscience.org/library/papers/41462859 | PubMed |
| 41345959 | YAP-induced MAML1 cooperates with STAT3 to drive hepatocellular carcinoma progression. | Exp Hematol Oncol | 2025 | https://conductscience.org/library/papers/41345959 | PubMed |
Genes20
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33330100
GET https://conductscience.org/api/papers/v1/33330100/references?page=2